ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment and tocilizumab"

  • Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting

    Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan

    Yoshiya Tanaka1, Hideto Kameda2, Kazuyoshi Saito3, Yuko Kaneko4, Eiichi Tanaka5, Shinsuke Yasuda6, Naoto Tamura7, Keishi Fujio8, Takao Fujii9, Toshihisa Kojima10, Tatsuhiko Anzai11, Chikuma Hamada12, Yoshihisa Fujino13, Shinya Matsuda13 and Hitoshi Kohsaka14, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 2Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, 3Tobata General Hospital, Fukuoka, Japan, 4Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 5Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 6Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 7Department of Internal Medicine and Rheumatology, Juntedo University School of Medicine, Tokyo, Japan, 8Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, 9Department of Rheumatism and Collagen Disease, Wakayama Medical University, Wakayama, Japan, 10Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, 11Data Science Division, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan, 12Department of Information and Computer Technology, Tokyo University of Science, Tokyo, Japan, 13Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 14Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

    Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…
  • Abstract Number: 1039 • 2015 ACR/ARHP Annual Meeting

    The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response

    Burkhard Leeb1,2, Raimund Lunzer3, Peter Fasching4, Manfred Herold5, O. Zamani6, Winfried Graninger7 and OPTIMISE trial Investigators, 12nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria, 2Department of Clinical Rheumatology, Karl Landsteiner Society, Stockerau, Austria, 3Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, 4Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, 5Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, 6Rheumazentrum Favoriten, Wien, Austria, 7Rheumatology and Immunology, Medical University of Graz, Graz, Austria

    Background/Purpose: An Austrian multi-center study of the effect on disease activity and the safety of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus TCZ Monotherapy…
  • Abstract Number: 1646 • 2015 ACR/ARHP Annual Meeting

    Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting? the ACT-Solo Study: An Analysis of Efficacy and Safety at 12 Months

    Jacques Tebib1, Isabelle Idier2, Mathieu Coudert3, David Pau4, Jean-Francis Maillefert5 and Rene-Marc Flipo6, 1Rheumatology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France, 2Chugai Pharma, La Defense, France, 3Statistics, Experis IT, Nanterre, France, 4Statistics, Roche, Boulogne-Billancourt, France, 5Rheumatology, University Hospital, Dijon, France, 6Rheumatology, University Hospital, Lille, France

    Background/Purpose: Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…
  • Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting

    The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis

    Yoshifumi Tada1, Syuichi Koarada2, Nobuyuki Ono2, Akihito Maruyama2, Satoko Tashiro2, Yukiko Tokuda2, Yukihide Ono2, Yoshinobu Nakao2 and Akihide Ohta3, 1Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, 2Rheumatology, Saga University, Saga, Japan, 3Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan

    Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…
  • Abstract Number: 1667 • 2015 ACR/ARHP Annual Meeting

    Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis

    Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Canestri, Clara Di Mario, Marcin Nowik and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: Tocilizumab (TCZ) is an effective treatment for Rheumatoid Arthritis (RA) and it is a modifier of B cell subsets in vivo, inducing changes in…
  • Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting

    Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study

    Ernest H. Choy1, Corrado Bernasconi2, Maher Aassi2, Jose F. Molina3 and Oscar M. Epis4, 1Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Centro Integral de Reumatologia Reumalab, Medellin, Colombia, 4Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy

    Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
  • Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting

    Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry

    Dimitrios A. Pappas1, Ani John2, Jeffrey R. Curtis3, George W. Reed4,5, Chitra Karki6, Robert Magner5, Joel M. Kremer7, Ashwini Shewade2 and Jeffrey D. Greenberg6,8, 1Columbia University, New York, NY, 2Genentech, Inc, South San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Corrona, LLC., Southborough, MA, 5University of Massachusetts Medical School, Worcester, MA, 6Corrona, LLC, Southborough, MA, 7Albany Medical College and The Center for Rheumatology, Albany, NY, 8NYU School of Medicine, New York, NY

    Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
  • Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting

    Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial

    Gerd Burmester1, William Rigby2, Ronald F. van Vollenhoven3, Jonathan Kay4, Andrea Rubbert-Roth5, Ricardo Blanco6, Ariella Kelman7, Sophie Dimonaco8 and Nina Mitchell8, 1Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Karolinska Institute, Stockholm, Sweden, 4UMass Memorial Medical Center, Worcester, MA, 5University of Cologne, Cologne, Germany, 6Hospital Marques de Valdecilla, Santander, Spain, 7Genentech, South San Francisco, CA, 8Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
  • Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting

    ALX-0061, an Anti-IL-6R Nanobody® for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab

    Maarten Van Roy1, Ariella Van De Sompel2, Kristi De Smet2, Jasper Jacobs2, Tinneke Denayer2 and Hans Ulrichts3, 1Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 2Ablynx N.V., Zwijnaarde, Belgium, 3Pharmacology, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…
  • Abstract Number: 519 • 2014 ACR/ARHP Annual Meeting

    Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study

    Boulos Haraoui1, Gustavo Casado2, Elke Theander3, Laszlo Czirják4, Andrew Taylor5, Peter Button6, Lykke Hinsch Gylvin7 and Roberto Caporali8, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Hospital Militar Central, Buenos Aires, Argentina, 3Skane University Hospital Malmö, Lund University, Malmö, Sweden, 4University of Pécs, Pécs, Hungary, 5Royal Perth Hospital, Perth, Australia, 6Roche Products Pty Limited, Dee Why, Australia, 7F. Hoffmann-La Roche, Basel, Switzerland, 8Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy

    Background/Purpose: Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in…
  • Abstract Number: 517 • 2014 ACR/ARHP Annual Meeting

    Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results

    Boulos Haraoui1, Shahin Jamal2, Vandana Ahluwalia3, Tarang Manchanda4 and Majed Khraishi5, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Department of Rheumatology, University of British Columbia, Vancouver, BC, Canada, 3William Osler Health Center, Brampton, ON, Canada, 4Hoffmann-La Roche Canada, Mississauga, ON, Canada, 5Nexus Clinical Research, St John's, NF, Canada

    Background/Purpose Tocilizumab (TCZ) has been approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or as combination with disease-modifying antirheumatic drugs…
  • Abstract Number: 2767 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial

    Gerd Burmester1, William Rigby2, Ronald F. van Vollenhoven3, Jonathan Kay4, Andrea Rubbert-Roth5, Ariella Kelman6, Sophie Dimonaco7 and Nina Mitchell7, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH, 3Karolinska Institute, Stockholm, Sweden, 4UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 5University of Cologne, Cologne, Germany, 6Genentech, South San Francisco, CA, 7Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Recent recommendations support intensive treatment of patients (pts) with early rheumatoid arthritis (RA) to achieve remission or low disease activity.1-3 Tocilizumab (TCZ) was not…
  • Abstract Number: 2364 • 2013 ACR/ARHP Annual Meeting

    Baseline Procalcitonin Levels Are Predictive Marker Of Remission In Biologic naïve Patients With Rheumatoid Arthritis Treated With Tocilizumab: Result From 24 Weeks Of Follow-Up

    Soichiro Tsuji1, Akiko Yura2, Michihito Katayama1, Satoru Teshigawara1, Maiko Yoshimura1, Eriko Tanaka1, Yoshinori Harada2, Yoshinori Katada2, Masato Matsushita3, Shiro Ohshima4, Jun Hashimoto1 and Yukihiko Saeki4, 1Dept of Rheumatology, Rheumatology,Osaka-Minami Medical Center, Kawachinagano City, Japan, 2Dept of Allergology, Allergology,Osaka-Minami Medical Center, Kawachinagano City, Japan, 3Rheumatology, Rheumatology,Osaka-Minami Medical Center, Kawachinagano City, Japan, 4Dept of Clinical Research, Clinical Research,Osaka-Minami Medical Center, Kawachinagano City, Japan

    Background/Purpose: , :Procalcitonin(PCT) is a useful marker of infection. PCT-mRNA increases expression from peripheral blood mononuclear cells by stimulation of a pro inflammatory cytokine, IL-6…
  • Abstract Number: 1441 • 2013 ACR/ARHP Annual Meeting

    Predictive Factors Of Response To Tocilizumab In Patients With Active Rheumatoid Arthritis

    Maria Victoria Hernández1, Javier Narvaez2, Raimon Sanmarti3, Delia Reina4, Cesar Diaz-Torne5, Berta Magallares5, Arturo Rodriguez de la Serna5, José María Llobet5, Hector Corominas4 and Joan Miquel Nolla2, 1Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 4Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 5Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose: To analyze the efficacy and identify predictors of response to tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods: A multicenter ambispective observational study…
  • Abstract Number: 1429 • 2013 ACR/ARHP Annual Meeting

    Adiponectin Levels Are Increased After Tocilizumab Therapy Among Adults With Rheumatoid Arthritis: Results From The Measure Study

    Hoda Mirjafari1, Micki Klearman2, Jianmei Wang3, Naveed Sattar4 and Jon T. Giles5, 1Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, Manchester Academic Health Science Centre; The University of Manchester; and Roche;, Manchester, United Kingdom, 2Roche, South San Francisco, CA, 3Roche Products Ltd., Welwyn Garden City, United Kingdom, 4University of Glasgow, Glasgow, United Kingdom, 5Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY

    Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients (pts) with rheumatoid arthritis (RA). Adiponectin has been shown to have anti-inflammatory and…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology